Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
MIMETAS
AddedJul 22, 2026
UpdatedJul 22, 2026
MIMETAS

MIMETAS

Series B

MIMETAS develops organ-on-a-chip human tissue and disease models used in drug discovery and safety testing.

HQ
Oegstgeest, NL
Founded
2013
Overview
Analysis
Compare
Fundraising
Employees
News
Website

MIMETAS builds 3D human tissue and disease models on its OrganoPlate organ-on-a-chip platform, supporting pharmaceutical research across immunology, oncology, metabolic, infectious, neurology, and ADME-toxicity studies. Pharmaceutical companies use its models and contract research services to assess drug efficacy and safety earlier in development.

Founded in 2013 in Leiden, the Netherlands, the company also operates offices in the United States and Japan, manufacturing OrganoPlate chips under cleanroom conditions in Enschede. Its offerings include the OrganoPlate platform, OrganoReady, and OrganoAccess product lines alongside contract research services.

MIMETAS - Products & Services

  • Contract Research Services logo

    Contract Research Services

    MIMETAS provides contract research services building custom organ-on-a-chip disease models and assays for pharmaceutical drug discovery.

    Competing Products

    Emulate logo
  • OrganoAccess logo

    OrganoAccess

    OrganoAccess is MIMETAS' perfusable vascular bed product for advanced 3D tissue modeling on the OrganoPlate Graft UF platform.

    Competing Products

    Emulate logo
  • OrganoReady logo

    OrganoReady

    OrganoReady is MIMETAS' ready-to-use Assay Ready tissue model product line for organ-on-a-chip drug testing.

    Competing Products

    Emulate logo
  • OrganoPlate logo

    OrganoPlate

    OrganoPlate is a mass-produced organ-on-a-chip microfluidic platform for 3D human tissue and disease modeling in drug discovery.

    Competing Products

    Emulate logo
    Emulate logo
    Emulate logo
    Emulate logo

MIMETAS - Similar Companies

Emulate logo

Emulate

emulatebio.com

MIMETAS - Quick Facts

Who are MIMETAS' competitors?

Companies similar to MIMETAS include Emulate.

When was MIMETAS founded?

MIMETAS was founded in 2013.

Where is MIMETAS' headquarters located?

MIMETAS' headquarters is located in Oegstgeest, NL.

When was MIMETAS' last funding round?

MIMETAS' most recent funding round was for $20.5M (USD) in April 2018.

How much has MIMETAS raised to-date?

As of Apr 11, 2018, MIMETAS has raised a total of $25.7M (USD).

How many employees does MIMETAS have?

MIMETAS has 100 employees as of Jan 1, 2026.

MIMETAS - Classification

Industry
  • Biotechnology Research
Ownership
  • Privately Held
Technology
  • Microfluidics
Geographic Exposure
  • Europe
Model
  • Manufacturer
Revenue
  • Product Sales
  • Service Fees
Customer
  • Pharmaceutical Manufacturers